Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (50) 50
Patent (18) 18
Publication (9) 9
Book / eBook (6) 6
Data Set (2) 2
Book Review (1) 1
Dissertation (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (29) 29
male (28) 28
index medicus (27) 27
agriculture (18) 18
animal husbandry (18) 18
beer (18) 18
biochemistry (18) 18
chemistry (18) 18
compositions or test papers therefor (18) 18
compositions thereof (18) 18
condition-responsive control in microbiological orenzymological processes (18) 18
culture media (18) 18
enzymology (18) 18
female (18) 18
fishing (18) 18
forestry (18) 18
general tagging of cross-sectional technologies spanning over several sections of the ipc (18) 18
general tagging of new technological developments (18) 18
human necessities (18) 18
hunting (18) 18
measuring or testing processes involving enzymes, nucleicacids or microorganisms (18) 18
metallurgy (18) 18
microbiology (18) 18
microorganisms or enzymes (18) 18
mutation or genetic engineering (18) 18
new plants or processes for obtaining them (18) 18
plant reproduction by tissue culture techniques (18) 18
processes of preparing such compositions (18) 18
propagating, preserving or maintaining microorganisms (18) 18
spirits (18) 18
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (18) 18
technologies for adaptation to climate change (18) 18
technologies or applications for mitigation or adaptation againstclimate change (18) 18
trapping (18) 18
vinegar (18) 18
wine (18) 18
treatment outcome (11) 11
adolescent (10) 10
adult (10) 10
aged (10) 10
middle aged (10) 10
abridged index medicus (9) 9
risk factors (9) 9
child (8) 8
prostate cancer (8) 8
children (7) 7
follow-up studies (7) 7
prostatic neoplasms - drug therapy (7) 7
usage (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
article (6) 6
clinical trials (6) 6
depression (6) 6
oncology (6) 6
prostatic neoplasms - pathology (6) 6
schools (6) 6
surveys and questionnaires (6) 6
teenagers (6) 6
time factors (6) 6
united states (6) 6
adolescents (5) 5
aged, 80 and over (5) 5
education (5) 5
english language (5) 5
medical research (5) 5
metastasis (5) 5
prospective studies (5) 5
prostate-specific antigen - blood (5) 5
psychiatry (5) 5
research (5) 5
survival (5) 5
age factors (4) 4
americanismos (4) 4
americanisms (4) 4
analysis (4) 4
behavior (4) 4
cognitive therapy (4) 4
dictionaries (4) 4
disease-free survival (4) 4
docetaxel (4) 4
inglés (4) 4
medicine, general & internal (4) 4
outcomes (4) 4
prostatic neoplasms - mortality (4) 4
randomized controlled-trial (4) 4
self-harm (4) 4
studies (4) 4
zoledronic acid (4) 4
androgen antagonists - administration & dosage (3) 3
androgen antagonists - adverse effects (3) 3
anglais (3) 3
child psychopathology (3) 3
children & youth (3) 3
confidence intervals (3) 3
depression - psychology (3) 3
depression, mental (3) 3
dialects (3) 3
dictionnaires (3) 3
diphosphonates - administration & dosage (3) 3
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (75) 75
French (5) 5
Spanish (4) 4
German (2) 2
Chinese (1) 1
Japanese (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
by James, Nicholas D, Prof and Sydes, Matthew R, MSc and Clarke, Noel W, Prof and Mason, Malcolm D, Prof and Dearnaley, David P, Prof and Spears, Melissa R, MSc and Ritchie, Alastair W S, MD and Parker, Christopher C, MD and Russell, J Martin, FRCR and Attard, Gerhardt, MD PhD and de Bono, Johann, Prof and Cross, William, PhD and Jones, Rob J, Prof and Thalmann, George, Prof and Amos, Claire, PhD and Matheson, David, PhD and Millman, Robin and Alzouebi, Mymoona, FRCR and Beesley, Sharon, FRCR and Birtle, Alison J, MD and Brock, Susannah, FRCR and Cathomas, Richard, MD and Chakraborti, Prabir, FRCR and Chowdhury, Simon, MD and Cook, Audrey, FRCR and Elliott, Tony, PhD and Gale, Joanna, DM and Gibbs, Stephanie, FRCR and Graham, John D, FRCP and Hetherington, John, FRCS[Eng] and Hughes, Robert, FRCR and Laing, Robert, FRCR and McKinna, Fiona, FRCR and McLaren, Duncan B, FRCR, FRCP[Ed] and O'Sullivan, Joe M, Prof and Parikh, Omi, FRCR and Peedell, Clive, FRCR and Protheroe, Andrew, PhD and Robinson, Angus J, FRCR and Srihari, Narayanan, MD and Srinivasan, Rajaguru, FRCR and Staffurth, John, MD and Sundar, Santhanam, FRCR and Tolan, Shaun, MD and Tsang, David, MCRP and Wagstaff, John, Prof and Parmar, Mahesh K B, Prof and STAMPEDE Investigators and STAMPEDE investigators
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10024, pp. 1163 - 1177
Summary Background Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled... 
Internal Medicine | ANDROGEN-DEPRIVATION THERAPY | MEDICINE, GENERAL & INTERNAL | PREDNISONE | DESIGN | MITOXANTRONE | CABAZITAXEL | CLINICAL-TRIALS | OPEN-LABEL | CHEMOTHERAPY | ENZALUTAMIDE | ESTRAMUSTINE | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Aged, 80 and over | Adult | Diphosphonates - adverse effects | Prostatic Neoplasms - drug therapy | Taxoids - adverse effects | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Imidazoles - adverse effects | Docetaxel | Kaplan-Meier Estimate | Treatment Outcome | Diphosphonates - administration & dosage | Zoledronic Acid | Disease Progression | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Androgen Antagonists - administration & dosage | Androgen Antagonists - adverse effects | Survival analysis | Medical prognosis | Clinical trials | Hormone replacement therapy | Metastasis | Prostate cancer | Cancer therapies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
by James, Nicholas D and de Bono, Johann S and Spears, Melissa R and Clarke, Noel W and Mason, Malcolm D and Dearnaley, David P and Ritchie, Alastair W.S and Amos, Claire L and Gilson, Clare and Jones, Rob J and Matheson, David and Millman, Robin and Attard, Gerhardt and Chowdhury, Simon and Cross, William R and Gillessen, Silke and Parker, Christopher C and Russell, J. Martin and Berthold, Dominik R and Brawley, Chris and Adab, Fawzi and Aung, San and Birtle, Alison J and Bowen, Jo and Brock, Susannah and Chakraborti, Prabir and Ferguson, Catherine and Gale, Joanna and Gray, Emma and Hingorani, Mohan and Hoskin, Peter J and Lester, Jason F and Malik, Zafar I and McKinna, Fiona and McPhail, Neil and Money-Kyrle, Julian and O’Sullivan, Joe and Parikh, Omi and Protheroe, Andrew and Robinson, Angus and Srihari, Narayanan N and Thomas, Carys and Wagstaff, John and Wylie, James and Zarkar, Anjali and Parmar, Mahesh K.B and Sydes, Matthew R and STAMPEDE Investigators
The New England Journal of Medicine, ISSN 0028-4793, 07/2017, Volume 377, Issue 4, pp. 338 - 351
The addition of abiraterone and prednisolone to standard androgen-deprivation therapy as the first treatment for patients with locally advanced or metastatic... 
ZOLEDRONIC ACID | SURVIVAL | MEDICINE, GENERAL & INTERNAL | PLUS PREDNISONE | CONTROL ARM | STAMPEDE TRIAL | OPEN-LABEL | MULTISTAGE | RANDOMIZED CONTROLLED-TRIAL | DOCETAXEL | MULTIARM | Prednisolone - adverse effects | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms - radiotherapy | Prednisolone - administration & dosage | Prostatic Neoplasms - surgery | Humans | Middle Aged | Abiraterone Acetate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Abiraterone Acetate - administration & dosage | Neoplasm Metastasis - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Adult | Aged | Androgen Antagonists - administration & dosage | Androgen Antagonists - adverse effects | Prostatic Neoplasms - drug therapy | Androgen suppression therapy | Usage | Care and treatment | Prostate cancer | Prednisolone | Medical research | Prostate-specific antigen | Clinical trials | Endocrine therapy | Oncology | Metastasis | Radiation therapy | Cancer therapies | Metastases | Mens health | Androgens | Medical prognosis | Death | Prostate
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Abiraterone in Metastatic Prostate Cancer
by James, Nicholas D and Spears, Melissa R and Sydes, Matthew R
The New England journal of medicine, 10/2017, Volume 377, Issue 17, p. 1696
Prostatic Neoplasms | Androstenols | Humans | Androstenes | Male | Treatment Outcome | Abiraterone Acetate
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Abiraterone in Metastatic Prostate Cancer
by James, Nicholas D and Spears, Melissa R and Sydes, Matthew R
The New England journal of medicine, 10/2017, Volume 377, Issue 17, p. 1696
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)
by James, Nicholas David and Spears, Melissa R and Clarke, Noel W and Dearnaley, David P and De Bono, Johann S and Gale, Joanna and Hetherington, John and Hoskin, Peter J and Jones, Robert J and Laing, Robert and Lester, Jason F and McLaren, Duncan and Parker, Christopher C and Parmar, Mahesh K.B and Ritchie, Alastair W.S and Russell, J. Martin and Strebel, Räto T and Thalmann, George N and Mason, Malcolm D and Sydes, Matthew R
European Urology, ISSN 0302-2838, 2014, Volume 67, Issue 6, pp. 1028 - 1038
Abstract Background Prostate cancer (PCa) is the second most common disease among men worldwide. It is important to know survival outcomes and prognostic... 
Urology | Control arm cohort | Hormone-naïve | Time to progression | Metastatic | Prospective data | Prostate cancer | Survival | Natural history | Prognostic factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis
by Rydzewska, Larysa H.M and Burdett, Sarah and Vale, Claire L and Clarke, Noel W and Fizazi, Karim and Kheoh, Thian and Mason, Malcolm D and Miladinovic, Branko and James, Nicholas D and Parmar, Mahesh K.B and Spears, Melissa R and Sweeney, Christopher J and Sydes, Matthew R and Tran, NamPhuong and Tierney, Jayne F and STOPCaP Abiraterone Collaborators
European Journal of Cancer, ISSN 0959-8049, 10/2017, Volume 84, pp. 88 - 101
There is a need to synthesise the results of numerous randomised controlled trials evaluating the addition of therapies to androgen deprivation therapy (ADT)... 
Systematic review | Androgen deprivation therapy | Abiraterone | Prostate cancer | Metastases | Meta-analysis | SURVIVAL | RANDOMIZED-TRIALS | ONCOLOGY | INDIVIDUAL PARTICIPANT DATA | Neoplasms, Hormone-Dependent - mortality | Age Factors | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Grading | Time Factors | Antineoplastic Agents, Hormonal - therapeutic use | Prednisolone - therapeutic use | Odds Ratio | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Androstenes - adverse effects | Risk Factors | Androstenes - therapeutic use | Treatment Outcome | Clinical Trials as Topic | Lymphatic Metastasis | Chi-Square Distribution | Prostatic Neoplasms - mortality | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Hormone-Dependent - pathology | Androgen Antagonists - therapeutic use | Aged | Neoplasms, Hormone-Dependent - drug therapy | Androgen Antagonists - adverse effects | Prednisone - therapeutic use | Metastasis | Hormones | Analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
by Sydes, M R and Spears, M R and Mason, M D and Clarke, N W and Dearnaley, D P and de Bono, J S and Attard, G and Chowdhury, S and Cross, W and Gillessen, S and Malik, Z I and Jones, R and Parker, C C and Ritchie, A W S and Russell, J M and Millman, R and Matheson, D and Amos, C and Gilson, C and Birtle, A and Brock, S and Capaldi, L and Chakraborti, P and Choudhury, A and Evans, L and Ford, D and Gale, J and Gibbs, S and Gilbert, D C and Hughes, R and McLaren, D and Lester, J F and Nikapota, A and O'Sullivan, J and Parikh, O and Peedell, C and Protheroe, A and Rudman, S M and Shaffer, R and Sheehan, D and Simms, M and Srihari, N and Strebel, R and Sundar, S and Tolan, S and Tsang, D and Varughese, M and Wagstaff, J and Parmar, M K B and James, N D and STAMPEDE Investigators and The STAMPEDE Investigators
Annals of Oncology, ISSN 0923-7534, 05/2018, Volume 29, Issue 5, pp. 1235 - 1248
Abstract Background Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival... 
Head-to-head | Treatment | Randomised | Abiraterone | Prostate cancer | Docetaxel | treatment | prostate cancer | randomised | abiraterone | head-to-head | docetaxel | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Abiraterone in Metastatic Prostate Cancer
by de Bono, Johann and Eisenberger, Mario and Sartor, Oliver and Tannock, Ian F and Ismaili, Nabil and Guessous, Fadila and James, Nicholas D and Spears, Melissa R and Sydes, Matthew R and Fizazi, Karim and Chi, Kim N
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 17, pp. 1694 - 1698
To the Editor: Fizazi et al. (July 27 issue) 1 report on the LATITUDE trial, and in the same issue, James et al. 2 report on the Systemic Therapy in Advancing... 
MEDICINE, GENERAL & INTERNAL | Androstenes | Prostatic Neoplasms | Male | Androstenols | Humans
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial
by Attard, Gerhardt and Sydes, Matthew R and Mason, Malcolm D and Clarke, Noel W and Aebersold, Daniel and de Bono, Johann S and Dearnaley, David P and Parker, Chris C and Ritchie, Alastair W.S and Russell, J. Martin and Thalmann, George and Cassoly, Estelle and Millman, Robin and Matheson, David and Schiavone, Francesca and Spears, Melissa R and Parmar, Mahesh K.B and James, Nicholas D
European Urology, ISSN 0302-2838, 2014, Volume 66, Issue 5, pp. 799 - 802
Take Home Message There are compelling reasons to study the addition of both enzalutamide and abiraterone, in combination, to standard-of-care for... 
Urology | UROLOGY & NEPHROLOGY | RECEPTOR | INCREASED SURVIVAL | INHIBITOR | ACETATE | METASTATIC PROSTATE-CANCER | Medical colleges | Corticosteroids | Clinical trials | Prednisone | Hormones | Prostate cancer | Steroids
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Adding celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: Long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial
by Mason, Malcolm D and Clarke, Noel W and James, Nicholas D and Dearnaley, David P and Spears, Melissa R and Ritchie, Alastair W.S and Attard, Gerhardt and Cross, William and Jones, Rob J and Parker, Christopher C and Russell, J. Martin and Thalmann, George N and Schiavone, Francesca and Cassoly, Estelle and Matheson, David and Millman, Robin and Rentsch, Cyrill A and Barber, Jim and Gilson, Clare and Ibrahim, Azman and Logue, John and Lydon, Anna and Nikapota, Ashok D and O'Sullivan, Joe M and Porfiri, Emilio and Protheroe, Andrew and Srihari, Narayanan Nair and Tsang, David and Wagstaff, John and Wallace, Jan and Walmsley, Catherine and Parmar, Mahesh K.B and Sydes, Matthew R and STAMPEDE Investigators and for the STAMPEDE Investigators
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 14, pp. 1530 - 1541
Purpose Systemic Therapy for Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy is a randomized controlled trial using a multiarm, multistage,... 
RADIOTHERAPY | ONCOLOGY | STAMPEDE TRIAL | CYCLOOXYGENASE-2 INHIBITORS | DRUGS | ANDROGEN DEPRIVATION THERAPY | ORIGINAL REPORTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols
by Parmar, Mahesh KB and Sydes, Matthew R and Cafferty, Fay H and Choodari-Oskooei, Babak and Langley, Ruth E and Brown, Louise and Phillips, Patrick PJ and Spears, Melissa R and Rowley, Sam and Kaplan, Richard and James, Nicholas D and Maughan, Timothy and Paton, Nicholas and Royston, Patrick J
Clinical Trials, ISSN 1740-7745, 10/2017, Volume 14, Issue 5, pp. 451 - 461
There is real need to change how we do some of our clinical trials, as currently the testing and development process is too slow, too costly and too... 
randomised trials | basket | multi-stage | umbrella | platform | Multi-arm | SURVIVAL | MEDICINE, RESEARCH & EXPERIMENTAL | RANDOMIZED CONTROLLED-TRIALS | DESIGN | ASPIRIN | CELECOXIB | METASTATIC PROSTATE-CANCER | BIOMARKERS | THERAPY | DISEASE | OUTCOMES | Clinical Trials, Phase III as Topic | Outcome Assessment (Health Care) | Humans | London | Clinical Protocols - standards | Male | Treatment Outcome | Research Design | Patient Selection | Randomized Controlled Trials as Topic | Clinical trials | Medical research | Design improvements
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis
by Larysa HM Rydzewska and Sarah Burdett and Claire L Vale and Noel W Clarke and Karim Fizazi and Thian Kheoh and Malcolm D Mason and Branko Miladinovic and Nicholas D James and Mahesh KB Parmar and Melissa R Spears and Christopher J Sweeney and Matthew R Sydes and NamPhuong Tran and Jayne F Tierney
European Journal of Cancer, ISSN 0959-8049, 10/2017, Volume 84, p. 88
Background: There is a need to synthesise the results of numerous randomised controlled trials evaluating the addition of therapies to androgen deprivation... 
Therapy | Deprivation | Toxicity | Endocrine therapy | Clinical trials | Systematic review | Prednisone | Metastasis | Survival | Subgroups | Metastases | Confidence intervals | Reduction | Randomization | Men | Acetic acid | Prostate cancer | Heart diseases | Prostate | Endocrinology | Prednisolone | Cancer | Acute toxicity
Journal Article
Details down arrow
13. Full Text Could a brief assessment of negative emotions and self-esteem identify adolescents at current and future risk of self-harm in the community? A prospective cohort analysis
by Phillips, Rhiannon and Spears, Melissa R and Montgomery, Alan A and Millings, Abigail and Sayal, Kapil and Stallard, Paul
BMC Public Health, ISSN 1471-2458, 2013, Volume 13, Issue 1, pp. 604 - 604
Background: Self-harm is common in adolescents, but it is often unreported and undetected. Available screening tools typically ask directly about self-harm and... 
Screening | Self-esteem | Negative emotions | Adolescents | Self-harm | YOUTH SUICIDE | DEPRESSION | MENTAL-HEALTH PROBLEMS | INJURY | SCHOOLS | CHILDRENS AUTOMATIC THOUGHTS | IDENTIFICATION | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | REPETITION | PREDICTORS | QUESTIONNAIRE | Predictive Value of Tests | Prospective Studies | Humans | England | Male | Psychometrics | Adolescent Health Services | Self-Injurious Behavior - diagnosis | Affect | Self Concept | Adolescent | Female | Surveys and Questionnaires | Adolescent Behavior | Child | Cohort Studies | High schools | Self-destructive behavior | Depression, Mental | Child psychopathology | Studies | Medical research | Teenagers | Self esteem | Self destructive behavior | Suicides & suicide attempts
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Testing many treatments within a single protocol over 10 years at MRC CTU at UCL: Multi-arm, multi stage platform, umbrella and basket protocols
by Parmar, Mahesh KB and Sydes, Matthew R and Cafferty, Fay H and Choodari-Oskooei, Babak and Langley, Ruth E and Brown, Louise and Phillips, Patrick PJ and Spears, Melissa R and Rowley, Sam and Kaplan, Richard and James, Nicholas D and Maughan, Timothy and Paton, Nicholas and Royston, Patrick J
Clinical trials (London, England), ISSN 1740-7745, 10/2017, Volume 14, Issue 5, pp. 451 - 461
There is real need to change how we do some of our clinical trials, as currently the testing and development process is too slow, too costly and too... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial
by Mason, Malcolm D and Clarke, Noel W and James, Nicholas D and Dearnaley, David P and Spears, Melissa R and Ritchie, Alastair W S and Attard, Gerhardt and Cross, William and Jones, Rob J and Parker, Christopher C and Russell, J Martin and Thalmann, George N and Schiavone, Francesca and Cassoly, Estelle and Matheson, David and Millman, Robin and Rentsch, Cyrill A and Barber, Jim and Gilson, Clare and Ibrahim, Azman and Logue, John and Lydon, Anna and Nikapota, Ashok D and O'Sullivan, Joe M and Porfiri, Emilio and Protheroe, Andrew and Srihari, Narayanan Nair and Tsang, David and Wagstaff, John and Wallace, Jan and Walmsley, Catherine and Parmar, Mahesh K B and Sydes, Matthew R and STAMPEDE Investigators
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 05/2017, Volume 35, Issue 14, p. 1530
Purpose Systemic Therapy for Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy is a randomized controlled trial using a multiarm, multistage,... 
Celecoxib - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Cause of Death | Early Termination of Clinical Trials | Time Factors | Aged, 80 and over | Adult | Gonadotropin-Releasing Hormone - agonists |